Claims (1)
1362935 年10月"~丨8曰修JT替換頁I 十、申請專利範圍 1· 一種改善胰島素耐受性的複合物，包括一山苦瓜 (Momordica Charantia Linn)萃取物及一螺旋藻複合物之一 酒精萃取物’其中該山苦瓜萃取物及該螺旋藻複合物的重 量比係實質介於1 : 5至1 : 2之間。 2. 如申請專利範圍第1項所述之改善胰島素耐受性的複合 物，係一口服錠劑、一口服散劑或一口服液劑。 3. 如申請專利範圍第1項所述之改善胰島素耐受性的複合 物’更包括一載體、一添加劑、一辅劑或—包覆劑。 4. 一種可同時增加第Π型糖尿病患血液中氧化物酶體增殖 物活化受體 _γ (Per〇xis〇me pr〇Uferat〇r activated receptor-γ，PPAR_Y)、胰島素受體（Insulin recept〇r)、胰島 素受體基質（Insulin receptor substrate，IRs)及葡萄糖轉運 蛋白-4(GLUT-4)濃度的複合物，包括一山苦瓜萃取物及一 螺旋藻複合物之一酒精萃取物，其中該山苦瓜萃取物及該 螺旋藻複合物的重量比係實質介於1 : 5至〖：2之間。 5. 如申請專利範圍第4項所述之可同時増加第η型糖尿病 患血液中氧化物酶體增殖物活化受體-γ、胰島素受體、膜島 素受體基質及葡萄糖轉運蛋白-4濃度的複合物，係一口服 24 1362935 18日修正替換頁 錠劑、一口服散劑或一口服液劑。 6.如申請專利範圍帛4項所述之可同時增加第^型糖尿病 患血液中氧化物酶體增殖物活化受體_丫、胰島素受體、胰島 素受體基質及葡萄糖轉運蛋白_4濃度的複合物^更包括一 載體、一添加劑、一輔劑或一包覆劑。 7. -種可同時降低第n型糖尿病患血液中葡萄糖濃产、三 酸甘油脂濃度、姨島素濃度的複合物，包括一山苦瓜萃： 物及一螺旋藻複合物之-酒精萃取物，其中該山苦瓜萃取 物及該螺旋藻複合物的重量比係實質介於1: 5至之 間。 8.如申請專利範圍帛7項所述之可同時降低第辽型糖尿病 〜液中葡萄糖濃度、三酸甘油脂濃度、騰島素濃度的複 合物’係-口服錠劑、—口服散劑或一口服液劑。 9’如申明專利範圍第7項所述之可同時降低第π型糖尿病 患血液中葡萄糖濃度、三酸甘油脂濃度、胰島素;農度的複合 物’更包括—載體、-添加劑、一輔劑或一包覆劑。 25October 1362935"~丨8曰修JT replacement page I X. Patent application scope 1. A compound that improves insulin resistance, including Momordica Charantia Linn extract and a spirulina complex An alcoholic extract wherein the weight ratio of the extract of the bitter gourd and the spirulina complex is substantially between 1:5 and 1:2. 2. A compound for improving insulin resistance as described in claim 1 of the patent application is an oral lozenge, an oral powder or an oral liquid. 3. The composition for improving insulin resistance as described in claim 1 further comprises a carrier, an additive, an adjuvant or a coating agent. 4. A method for simultaneously increasing the levels of oxidase-activated receptor-γ (PPAR_Y) and insulin receptor (Insulin recept〇) in the blood of patients with type 2 diabetes mellitus r) a complex of an insulin receptor substrate (IRs) and a glucose transporter-4 (GLUT-4) concentration, comprising an extract of a bitter gourd extract and an alcoholic extract of a spirulina complex, wherein The weight ratio of the mountain bitter gourd extract and the spirulina complex is substantially between 1:5 and 〖:2. 5. As described in the fourth paragraph of the patent application, the oxidized proliferator-activated receptor-γ, insulin receptor, membrane receptor matrix and glucose transporter-4 in the blood of patients with type XX diabetes can be simultaneously added. The concentration of the complex is an oral 24 1362935 18-day modified replacement tablet, an oral powder or an oral solution. 6. As described in the scope of patent application 帛 4, it can simultaneously increase the concentration of oxidase-proliferating receptor receptor 丫, insulin receptor, insulin receptor matrix and glucose transporter _4 in the blood of patients with type 2 diabetes. The composite further comprises a carrier, an additive, an adjuvant or a coating agent. 7. A compound that simultaneously reduces the concentration of glucose in the blood, the concentration of triglyceride, and the concentration of sulphonin in patients with type n diabetes, including a bitter gourd extract: a substance and a spirulina complex - an alcohol extract Wherein the weight ratio of the extract of the bitter gourd and the spirulina complex is substantially between 1:5 and about. 8. As described in the scope of patent application 帛7, the complex of 'Liao type diabetes mellitus~ liquid glucose concentration, triglyceride concentration, and the concentration of Tengdasu can be reduced at the same time. Oral liquid. 9', as described in claim 7 of the scope of patents, can simultaneously reduce the blood glucose concentration, triglyceride concentration, insulin; the complex of agricultural degree', including - carrier, - additive, an adjuvant Or a coating agent. 25